Oncotarget

Corrections:

Correction: Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation

PDF  |  How to cite

Oncotarget. 2020; 11:1575-1575. https://doi.org/10.18632/oncotarget.27542

Metrics: PDF 428 views  |   ?  

Shao-Qian Sun1,*, Xiaobin Gu1,*, Xian-Shu Gao1, Yi Li2, Hongliang Yu3, Wei Xiong4, Hao Yu1, Wen Wang1, Yingbo Li2, Yingqi Teng5, Demin Zhou2

1 Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China
2 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China
3 Department of Radiation Oncology, Jiangsu Cancer Hospital Affiliated with Nanjing Medical University, Nanjing, China
4 Tangshan People’s Hospital, Hebei, China
5 Beijing Reciproca Pharmaceutical Co. Ltd., Beijing, China
* These authors contributed equally to this work

Published: April 28, 2020

This article has been corrected: In Figure 2C, in the column labeled ‘4GY’, the picture of Indocin- is mistakenly identical to the picture for Indocin+. The corrected Figure 2C, obtained using original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:48050–48058. DOI: https://doi.org/10.18632/oncotarget.10347.

Figure 2: Indomethacin, an inhibitor of AKR1C3 activity, overcomes radiation resistance. (A) AKR1C3-over cells and control cells were treated with or without 20 mmol/ indomethacin for 2 days, and western blotting was performed; (B, C) AKR1C3-over cells and Control cells were treated with or without 20 mmol/ indomethacin for 2 days, and clonogenic assay was performed; (D) Colony forming efficiency were calculated and results are presented as means SD of two experiments performed in duplicate.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27542